Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 103

1.

Comprehensive systematic review summary: Treatment of cerebellar motor dysfunction and ataxia: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.

Zesiewicz TA, Wilmot G, Kuo SH, Perlman S, Greenstein PE, Ying SH, Ashizawa T, Subramony SH, Schmahmann JD, Figueroa KP, Mizusawa H, Schöls L, Shaw JD, Dubinsky RM, Armstrong MJ, Gronseth GS, Sullivan KL.

Neurology. 2018 Feb 9. pii: 10.1212/WNL.0000000000005055. doi: 10.1212/WNL.0000000000005055. [Epub ahead of print]

PMID:
29440566
2.

Quality improvement in neurology: Essential Tremor Quality Measurement Set.

Zesiewicz TA, Sullivan KL, Ponce de Leon M, Bennett A, Hohler AD.

Neurology. 2017 Sep 19;89(12):1291-1295. doi: 10.1212/WNL.0000000000004372. Epub 2017 Aug 23. No abstract available.

PMID:
28835402
3.

Longitudinal gait and balance decline in Friedreich's Ataxia: A pilot study.

Zesiewicz TA, Stephenson JB, Kim SH, Sullivan KL, Jahan I, Huang Y, Salemi JL, Wecker L, Shaw JD, Gooch CL.

Gait Posture. 2017 Jun;55:25-30. doi: 10.1016/j.gaitpost.2017.03.019. Epub 2017 Mar 30.

PMID:
28411441
4.

A randomized, fixed-dose, dose-response study of ropinirole prolonged release in advanced Parkinson's disease.

Zesiewicz TA, Chriscoe S, Jimenez T, Upward J, Davy M, VanMeter S.

Neurodegener Dis Manag. 2017 Feb;7(1):61-72. doi: 10.2217/nmt-2016-0038. Epub 2017 Jan 25.

5.

A fixed-dose, dose-response study of ropinirole prolonged release in early stage Parkinson's disease.

Zesiewicz TA, Chriscoe S, Jimenez T, Upward J, VanMeter S.

Neurodegener Dis Manag. 2017 Feb;7(1):49-59. doi: 10.2217/nmt-2016-0039. Epub 2017 Jan 25.

6.

Emerging therapies in Friedreich's ataxia.

Aranca TV, Jones TM, Shaw JD, Staffetti JS, Ashizawa T, Kuo SH, Fogel BL, Wilmot GR, Perlman SL, Onyike CU, Ying SH, Zesiewicz TA.

Neurodegener Dis Manag. 2016;6(1):49-65. doi: 10.2217/nmt.15.73. Review.

7.

Essential tremor.

Zesiewicz TA, Kuo SH.

BMJ Clin Evid. 2015 Dec 15;2015. pii: 1206.

8.

Occupational Characteristics and Patterns as Risk Factors for Parkinson's Disease: A Case Control Study.

Sullivan KL, Mortimer JA, Wang W, Zesiewicz TA, Brownlee HJ, Borenstein AR.

J Parkinsons Dis. 2015;5(4):813-20. doi: 10.3233/JPD-150635.

PMID:
26444091
9.

Humoral factors in ALS patients during disease progression.

Ehrhart J, Smith AJ, Kuzmin-Nichols N, Zesiewicz TA, Jahan I, Shytle RD, Kim SH, Sanberg CD, Vu TH, Gooch CL, Sanberg PR, Garbuzova-Davis S.

J Neuroinflammation. 2015 Jun 28;12:127. doi: 10.1186/s12974-015-0350-4.

10.

Clinically meaningful parameters of progression and long-term outcome of Parkinson disease: An international consensus statement.

Puschmann A, Brighina L, Markopoulou K, Aasly J, Chung SJ, Frigerio R, Hadjigeorgiou G, Kõks S, Krüger R, Siuda J, Wider C, Zesiewicz TA, Maraganore DM.

Parkinsonism Relat Disord. 2015 Jul;21(7):675-82. doi: 10.1016/j.parkreldis.2015.04.029. Epub 2015 May 1. Review.

PMID:
25952959
11.

Randomized, controlled pilot trial of solifenacin succinate for overactive bladder in Parkinson's disease.

Zesiewicz TA, Evatt M, Vaughan CP, Jahan I, Singer C, Ordorica R, Salemi JL, Shaw JD, Sullivan KL; Non-Motor Working Group of the Parkinson Study Group (PSG).

Parkinsonism Relat Disord. 2015 May;21(5):514-20. doi: 10.1016/j.parkreldis.2015.02.025. Epub 2015 Mar 6.

PMID:
25814050
12.

Treatment of cerebellar ataxia.

Jones TM, Shaw JD, Sullivan K, Zesiewicz TA.

Neurodegener Dis Manag. 2014;4(5):379-92. doi: 10.2217/nmt.14.27. Review.

PMID:
25405651
13.

Autologous stem cell transplant with gene therapy for Friedreich ataxia.

Tajiri N, Staples M, Kaneko Y, Kim SU, Zesiewicz TA, Borlongan CV.

Med Hypotheses. 2014 Sep;83(3):296-8. doi: 10.1016/j.mehy.2014.05.022. Epub 2014 Jun 9.

14.

Author response.

Bhidayasiri R, Fahn S, Gronseth GS, Sullivan KL, Zesiewicz TA.

Neurology. 2014 Feb 18;82(7):643. No abstract available.

PMID:
24745039
15.

Author response.

Bhidayasiri R, Fahn S, Gronseth GS, Sullivan KL, Zesiewicz TA.

Neurology. 2013 Nov 26;81(22):1967. No abstract available.

PMID:
24416785
16.

Evidence-based guideline: Treatment of tardive syndromes: report of the Guideline Development Subcommittee of the American Academy of Neurology.

Lerner V, Miodownik C, Sheva B, Bhidayasiri R, Fahn S, Gronseth GS, Sullivan KL, Zesiewicz TA.

Neurology. 2013 Nov 26;81(22):1967. doi: 10.1212/01.wnl.0000439053.82390.26. No abstract available.

PMID:
24276337
17.

Effects of rotigotine transdermal system on non-motor symptoms in Parkinson's disease: an overview.

Zesiewicz TA, Martinez-Martin P.

Expert Rev Neurother. 2013 Dec;13(12):1329-42. doi: 10.1586/14737175.2013.859986. Review.

PMID:
24236902
18.

Clinical characteristics of patients with spinocerebellar ataxias 1, 2, 3 and 6 in the US; a prospective observational study.

Ashizawa T, Figueroa KP, Perlman SL, Gomez CM, Wilmot GR, Schmahmann JD, Ying SH, Zesiewicz TA, Paulson HL, Shakkottai VG, Bushara KO, Kuo SH, Geschwind MD, Xia G, Mazzoni P, Krischer JP, Cuthbertson D, Holbert AR, Ferguson JH, Pulst SM, Subramony SH.

Orphanet J Rare Dis. 2013 Nov 13;8:177. doi: 10.1186/1750-1172-8-177.

19.

Randomized trial of cognitive speed of processing training in Parkinson disease.

Edwards JD, Hauser RA, O'Connor ML, Valdés EG, Zesiewicz TA, Uc EY.

Neurology. 2013 Oct 8;81(15):1284-90. doi: 10.1212/WNL.0b013e3182a823ba. Epub 2013 Sep 6.

20.

Evidence-based guideline: treatment of tardive syndromes: report of the Guideline Development Subcommittee of the American Academy of Neurology.

Bhidayasiri R, Fahn S, Weiner WJ, Gronseth GS, Sullivan KL, Zesiewicz TA; American Academy of Neurology.

Neurology. 2013 Jul 30;81(5):463-9. doi: 10.1212/WNL.0b013e31829d86b6. Review. Erratum in: Neurology. 2013 Nov 26;81(22):1968.

PMID:
23897874
21.

Update on treatment of essential tremor.

Zesiewicz TA, Shaw JD, Allison KG, Staffetti JS, Okun MS, Sullivan KL.

Curr Treat Options Neurol. 2013 Aug;15(4):410-23. doi: 10.1007/s11940-013-0239-4.

PMID:
23881742
22.

Neuronal nicotinic receptor agonists improve gait and balance in olivocerebellar ataxia.

Wecker L, Engberg ME, Philpot RM, Lambert CS, Kang CW, Antilla JC, Bickford PC, Hudson CE, Zesiewicz TA, Rowell PP.

Neuropharmacology. 2013 Oct;73:75-86. doi: 10.1016/j.neuropharm.2013.05.016. Epub 2013 May 24.

23.

Methodological issues in clinical drug development for essential tremor.

Carranza MA, Snyder MR, Elble RJ, Boutzoukas AE, Zesiewicz TA.

Tremor Other Hyperkinet Mov (N Y). 2012;2. pii: tre-02-68-402-1. doi: 10.7916/D8P55M7F. Epub 2012 Aug 6.

24.

Multisite, double-blind, randomized, controlled study of pregabalin for essential tremor.

Zesiewicz TA, Sullivan KL, Hinson V, Stover NP, Fang J, Jahan I, Miller A, Carranza MA, Elble R.

Mov Disord. 2013 Feb;28(2):249-50. doi: 10.1002/mds.25264. Epub 2012 Dec 12. No abstract available.

PMID:
23238907
25.

Impact of discontinuing tremor suppressing medications following thalamic deep brain stimulation.

Favilla CG, Topiol DD, Zesiewicz TA, Wagle Shukla A, Foote KD, Jacobson CE 4th, Okun MS.

Parkinsonism Relat Disord. 2013 Feb;19(2):171-5. doi: 10.1016/j.parkreldis.2012.09.002. Epub 2012 Oct 11.

PMID:
23062997
26.

Self-perceived burden as a mediator of depression symptoms amongst individuals living with a movement disorder.

Dempsey LE, Karver MS, Labouliere C, Zesiewicz TA, De Nadai AS.

J Clin Psychol. 2012 Oct;68(10):1149-60. doi: 10.1002/jclp.21901. Epub 2012 Jul 19.

PMID:
22814900
27.

Placebo-controlled trial of lubiprostone for constipation associated with Parkinson disease.

Ondo WG, Kenney C, Sullivan K, Davidson A, Hunter C, Jahan I, McCombs A, Miller A, Zesiewicz TA.

Neurology. 2012 May 22;78(21):1650-4. doi: 10.1212/WNL.0b013e3182574f28. Epub 2012 May 9.

PMID:
22573627
28.

Cardiac dysfunction exacerbated by endocrinopathies in Friedreich ataxia: a case series.

Snyder M, Seyer L, Lynch DR, Resnick A, Zesiewicz TA.

J Child Neurol. 2012 Oct;27(10):1316-9. Epub 2012 Mar 8.

PMID:
22408141
29.

A randomized trial of varenicline (Chantix) for the treatment of spinocerebellar ataxia type 3.

Zesiewicz TA, Greenstein PE, Sullivan KL, Wecker L, Miller A, Jahan I, Chen R, Perlman SL.

Neurology. 2012 Feb 21;78(8):545-50. doi: 10.1212/WNL.0b013e318247cc7a. Epub 2012 Feb 8. Erratum in: Neurology. 2012 Jul 31;79(5):488.

PMID:
22323747
30.

Depressive symptoms in Parkinson disease: degree of association and rate of agreement of clinician-based and self-report measures.

Cimino CR, Siders CA, Zesiewicz TA.

J Geriatr Psychiatry Neurol. 2011 Dec;24(4):199-205. doi: 10.1177/0891988711422525.

PMID:
22228826
31.

Parkinson disease: the controversy of levodopa toxicity in Parkinson disease.

Zesiewicz TA.

Nat Rev Neurol. 2011 Dec 26;8(1):8-10. doi: 10.1038/nrneurol.2011.199. No abstract available.

PMID:
22198404
32.

Evidence-based guideline update: treatment of essential tremor: report of the Quality Standards subcommittee of the American Academy of Neurology.

Zesiewicz TA, Elble RJ, Louis ED, Gronseth GS, Ondo WG, Dewey RB Jr, Okun MS, Sullivan KL, Weiner WJ.

Neurology. 2011 Nov 8;77(19):1752-5. doi: 10.1212/WNL.0b013e318236f0fd. Epub 2011 Oct 19. Review.

33.

Patients' and caregivers' experiences of the impact of Parkinson's disease on health status.

Chiong-Rivero H, Ryan GW, Flippen C, Bordelon Y, Szumski NR, Zesiewicz TA, Vassar S, Weidmer B, García RE, Bradley M, Vickrey BG.

Patient Relat Outcome Meas. 2011 Mar;2011(2):57-70.

34.

Drug-induced hyperkinetic movement disorders by nonneuroleptic agents.

Zesiewicz TA, Sullivan KL.

Handb Clin Neurol. 2011;100:347-63. doi: 10.1016/B978-0-444-52014-2.00027-6. Review.

PMID:
21496594
35.

Delayed clinical improvement after deep brain stimulation-related subdural hematoma. Report of 4 cases.

Oyama G, Okun MS, Zesiewicz TA, Tamse T, Romrell J, Zeilman P, Foote KD.

J Neurosurg. 2011 Aug;115(2):289-94. doi: 10.3171/2011.3.JNS101424. Epub 2011 Apr 8.

PMID:
21476805
36.

Overview of essential tremor.

Zesiewicz TA, Chari A, Jahan I, Miller AM, Sullivan KL.

Neuropsychiatr Dis Treat. 2010 Sep 7;6:401-8.

37.

Reduction of circulating endothelial cells in peripheral blood of ALS patients.

Garbuzova-Davis S, Woods RL 3rd, Louis MK, Zesiewicz TA, Kuzmin-Nichols N, Sullivan KL, Miller AM, Hernandez-Ontiveros DG, Sanberg PR.

PLoS One. 2010 May 12;5(5):e10614. doi: 10.1371/journal.pone.0010614.

38.

Practice Parameter: treatment of nonmotor symptoms of Parkinson disease: report of the Quality Standards Subcommittee of the American Academy of Neurology.

Zesiewicz TA, Sullivan KL, Arnulf I, Chaudhuri KR, Morgan JC, Gronseth GS, Miyasaki J, Iverson DJ, Weiner WJ; Quality Standards Subcommittee of the American Academy of Neurology.

Neurology. 2010 Mar 16;74(11):924-31. doi: 10.1212/WNL.0b013e3181d55f24.

PMID:
20231670
39.

Sleep disorders in Parkinson's disease.

Jahan I, Hauser RA, Sullivan KL, Miller A, Zesiewicz TA.

Neuropsychiatr Dis Treat. 2009;5:535-40. Epub 2009 Nov 2.

40.

Potential influences of complementary therapy on motor and non-motor complications in Parkinson's disease.

Zesiewicz TA, Evatt ML.

CNS Drugs. 2009 Oct;23(10):817-35. doi: 10.2165/11310860-000000000-00000. Review.

PMID:
19739693
41.

Subjective improvement in proprioception in 2 patients with atypical Friedreich ataxia treated with varenicline (Chantix).

Zesiewicz TA, Sullivan KL, Gooch CL, Lynch DR.

J Clin Neuromuscul Dis. 2009 Jun;10(4):191-3. doi: 10.1097/CND.0b013e3181910074.

PMID:
19494730
42.

Stiff-person syndrome: commonly mistaken for hysterical paralysis.

Fleischman D, Madan G, Zesiewicz TA, Fleischman M.

Clin Neurol Neurosurg. 2009 Sep;111(7):644. doi: 10.1016/j.clineuro.2009.04.005. Epub 2009 May 26. No abstract available.

PMID:
19473753
43.

Fentanyl-induced bradykinesia and rigidity after deep brain stimulation in a patient with Parkinson disease.

Zesiewicz TA, Hauser RA, Freeman A, Sullivan KL, Miller AM, Halim T.

Clin Neuropharmacol. 2009 Jan-Feb;32(1):48-50. doi: 10.1097/WNF.0b013e31817e23e3.

PMID:
19471184
44.

Treatment of ataxia and imbalance with varenicline (chantix): report of 2 patients with spinocerebellar ataxia (types 3 and 14).

Zesiewicz TA, Sullivan KL.

Clin Neuropharmacol. 2008 Nov-Dec;31(6):363-5. doi: 10.1097/WNF.0b013e31818736a9.

PMID:
19050414
45.

Levetiracetam for stiff-person syndrome: report of 2 patients.

Shimberg WR, Patel NB, Sullivan KL, Hauser RA, Zesiewicz TA.

Clin Neuropharmacol. 2008 Sep-Oct;31(5):301-2. doi: 10.1097/WNF.0b013e31815f8df0.

PMID:
18836351
46.

Treatment of imbalance with varenicline Chantix(R): report of a patient with fragile X tremor/ataxia syndrome.

Zesiewicz TA, Sullivan KL, Freeman A, Juncos JL.

Acta Neurol Scand. 2009 Feb;119(2):135-8. doi: 10.1111/j.1600-0404.2008.01070.x. Epub 2008 Sep 3.

PMID:
18771524
47.

Deep brain stimulation of the ventral intermediate nucleus of the thalamus in medically refractory orthostatic tremor: preliminary observations.

Espay AJ, Duker AP, Chen R, Okun MS, Barrett ET, Devoto J, Zeilman P, Gartner M, Burton N, Miranda HA, Mandybur GT, Zesiewicz TA, Foote KD, Revilla FJ.

Mov Disord. 2008 Dec 15;23(16):2357-62. doi: 10.1002/mds.22271.

PMID:
18759339
48.

Red flags to spot the parkinsonian variant of multiple system atrophy.

Zesiewicz TA, Sullivan KL, Gooch CL.

Nat Clin Pract Neurol. 2008 Nov;4(11):596-7. doi: 10.1038/ncpneuro0881. Epub 2008 Aug 12.

PMID:
18695708
49.

Delayed thalamic intracranial hemorrhage in an essential tremor patient following deep brain stimulation.

Zesiewicz TA, Sullivan KL, Hoffmann M, Benes LM, Smith DA, Ward CL, Hauser RA.

Eur Neurol. 2008;59(3-4):187-9. doi: 10.1159/000114041. Epub 2008 Jan 29. No abstract available.

50.

Chorea as a side effect of gabapentin (Neurontin) in a patient with complex regional pain syndrome Type 1.

Zesiewicz TA, Shimberg WR, Hauser RA, Robinson W, Wilson MC, Sullivan KL.

Clin Rheumatol. 2008 Mar;27(3):389-90. Epub 2007 Oct 16.

PMID:
17938990

Supplemental Content

Loading ...
Support Center